Zynex, Inc. Provides Revenue Guidance for Fourth Quarter of 2020 and Full Year 2020
January 12, 2021 at 09:00 am EST
Share
Zynex, Inc. provides revenue guidance for fourth quarter of 2020 and full year 2020. For the fourth quarter of 2020, the Company is confirming its previous revenue estimate of between $25.5 and $26.5 million.
For full year 2021, revenue estimate is between $80 and $81 million. The revenue estimate is approximately 76% to 78% above last year's full year revenue of $45.5 million.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
